Rocket Lab Corp

Rocket Lab is a vertically integrated space company with two main lines of business: launching small satellites to orbit using its Electron rocket, and building spacecraft components and complete satellites for customers through its Space Systems division. Customers include the U.S. Department of Defense, NASA, and commercial satellite operators. The company makes money by charging for launches (per mission) and by selling spacecraft hardware, software, and engineering services on long-term contracts.

Revenue hit $601.8M in 2025, up 38% from $436.2M in 2024 and up from $244.6M in 2023 S2S5. That is genuinely strong growth, more than doubling in two years. Gross margin improved meaningfully to 34.4% in 2025 from 26.6% in 2024 S5, which shows the business is getting more efficient as it scales.

The company is still losing money. Operating loss was $228.8M in 2025 versus $189.8M in 2024 S5, and net loss was $198.2M in 2025 versus $190.2M in 2024 S5S6. Losses are widening in absolute terms, primarily because R&D spending jumped to $270.7M (45% of revenue) in 2025 from $174.4M (40% of revenue) in 2024 S5, almost entirely driven by Neutron rocket development.

Cash position is strong. The company holds $828.7M in cash and equivalents [XBRL] plus $270.2M in marketable securities, totaling roughly $1.1B in liquid assets S5S7. Long-term debt is $152.4M (the remaining convertible notes due 2029) [S5,XBRL], down sharply from $345.4M at the prior year-end after $199.3M in conversions S6S7. Total assets are $2.32B with shareholders equity of $1.72B [XBRL], a relatively clean balance sheet for a growth-stage aerospace company.

Operating cash flow was negative $165.5M in 2025, worse than negative $48.9M in 2024 S5S6. The company funded itself primarily through ATM equity offerings, raising $1.12B in net proceeds by selling 30.8M shares in 2025 S5S6. Capital expenditures were $156.3M [XBRL]. Stock-based compensation was $71.1M, or about 11.8% of revenue [S8,XBRL].

No dividends were paid and no share buybacks were conducted. The Direct Funding Agreement with the U.S. Department of Commerce actually restricts buybacks and dividends without prior approval S3S4.

Business segments: Rocket Lab operates two segments. Space Systems is the larger one at $402.8M revenue in 2025, up 30% year over year S5S7. Launch Services generated $199.0M in 2025, up 59% year over year, completing 21 missions S5S7. Launch is the faster-growing segment and the one with the most dramatic margin improvement, with cost per launch falling from $7.0M in 2023 to $5.7M in 2024 to $4.8M in 2025 S5.

Better on revenue and margins. The 38% revenue growth is real and broad-based across both segments S2. Gross margin expanding from 26.6% to 34.4% in one year is a significant operational improvement S5. Launch economics are clearly scaling: revenue per launch rose from $7.1M in 2023 to $8.5M in 2025, while cost per launch fell from $7.0M to $4.8M over the same period S5.

The backlog picture is excellent. Total backlog grew 73% to $1.85B at year-end 2025 from $1.07B at year-end 2024, including a single $816M contract from the Space Development Agency signed in December 2025 S5S7. That provides multi-year revenue visibility.

The challenge is operating cash burn accelerating from negative $48.9M in 2024 to negative $165.5M in 2025 S5S6, driven by Neutron development costs. The path to profitability depends heavily on whether Neutron can be built on schedule and win commercial contracts. The January 2026 tank test failure already pushed the first launch from mid-2026 to Q4 2026 S5, and further delays are a real possibility. Until Neutron either succeeds or the company scales Electron and Space Systems enough to cover overhead, expect continued large losses.

• Rocket Lab competes against SpaceX, Northrop Grumman, ULA, Blue Origin, Firefly, Boeing, Airbus, Lockheed Martin, and Raytheon across both launch and spacecraft segments S2. SpaceX is the dominant force in launch, and Rocket Lab explicitly notes it was the second most frequently launched orbital rocket in 2025 S2, which is a meaningful commercial positioning.
• In small satellite launch, Rocket Lab's Electron is the established leader in dedicated small-lift missions. Its differentiation is reliability (75 successful missions out of 78 total S2) and dedicated launch scheduling rather than rideshare.
• In Space Systems, competitors include large prime defense contractors. Rocket Lab's vertical integration (building solar cells, avionics, spacecraft buses, optical systems in-house) is a genuine cost and supply chain advantage they have built through five acquisitions S2.
• The company flags that non-U.S. competitors may have fewer ITAR and export control restrictions, giving them an advantage in serving some international customers S4. Neutron, if it succeeds, would put Rocket Lab into direct competition with SpaceX's Falcon 9 for medium-lift missions, a much larger market but a much harder fight.

Sir Peter Beck is CEO, President, and Chairman, and the filing flags him as a key-person risk with no life insurance policy maintained S3. In January 2025, his family trust converted 50.95M common shares into Series A Convertible Participating Preferred Stock, which carry as-converted voting rights and a board seat S8. Those preferred shares automatically convert back to common if Beck ceases to be CEO, dies, becomes disabled, or ownership falls below 5% S8. Five million of those shares were converted back to common in June 2025 S6S8. This structure concentrates both economic interest and governance control with Beck while he remains active.

No CEO or CFO changes are disclosed. Leadership appears stable. Insider ownership is concentrated at the founder level through the preferred stock structure, which generally aligns long-term incentives, though it also means limited checks on founder decision-making.

• Neutron is the big bet. Management is spending $270.7M per year in R&D [XBRL], with the majority going toward Neutron, a medium-lift reusable rocket targeting roughly 13,000 kg to orbit S2. If successful, this opens a market many times larger than Electron's small-lift niche. The first launch is now targeted for Q4 2026 after a tank test failure in January 2026 S5.
• Scaling Space Systems through contracts and acquisitions. The $816M SDA Tranche 3 contract signed in December 2025 S5 and the GEOST acquisition in August 2025 S6 show management is aggressively building its position as a full-service spacecraft manufacturer for the U.S. government.
• Vertical integration as a moat. Management has consistently acquired component manufacturers (solar cells, optical systems, avionics, reaction wheels) to control costs and supply chain for both internal and external customers S2.
• Electron economics. Management expects launch cadence to keep increasing and cost per launch to keep falling as production scales, improving margins on the existing business while Neutron is developed S5.

• HIGHOperating cash burn accelerated to negative $165.5M in 2025 from negative $48.9M in 2024 S5S6, and the company explicitly states it expects continued losses for at least the next 12 months and may never achieve profitability S2. The company is burning cash primarily to develop Neutron, which just experienced a test failure S5.
• HIGHDilution is significant and ongoing. In 2025 alone: 30.8M shares sold via ATM offerings for $1.12B in proceeds S5S6, plus 38.9M shares issued from convertible note conversions S7, plus ongoing stock-based compensation of $71.1M with $108.8M in unrecognized RSU compensation remaining S8. The convertible notes are currently in-the-money (stock price exceeded 130% of the $5.13 conversion price in Q4 2025) S7, meaning further share issuances from the remaining $155.7M in notes are likely.
• MEDU.S. government revenue concentration rose to 47% of 2025 revenues from 31% in 2023 S3. Top 5 customers represent 49% of revenue and 77% of backlog S3. A government shutdown in October 2025 already caused contract delays and workforce reductions at Wallops S3. Budget uncertainty under shifting federal priorities is a real revenue risk.
• MEDNeutron delay and development risk. The tank qualification failure in January 2026 pushed the target first launch to Q4 2026 S5, and management acknowledges further delays are possible. R&D spending was $270.7M in 2025, up 55% from $174.4M in 2024 S5, and these costs continue regardless of whether Neutron succeeds.
• MEDGEOST acquisition was excluded from management's internal control assessment because it represented 14% of total assets at year-end S6. That is a meaningful gap in financial control coverage for a recently acquired business.
• LOWForeign exchange exposure of approximately $126.8M in annual expenditures (roughly 15% of spending) is in New Zealand dollars with no hedging strategy in place S3.
• LOWSecurities class action filed February 2025 over alleged misstatements about Neutron development; the Motion to Dismiss was granted in November 2025 but an amended complaint was filed in December 2025 and a new Motion to Dismiss was filed in January 2026 S4. Litigation is ongoing.

Rocket Lab is a genuine, high-growth aerospace company that has built a real and expanding business, not just a promise. Revenue more than doubled in two years, gross margins are rising fast, and the backlog just hit $1.85B S5S7. The core risk is that the company is spending enormously on Neutron, a program that must succeed for the investment thesis to fully pay off, and the first test failure in January 2026 is a reminder of how hard this is. Investors need to believe Neutron gets built, the Space Systems backlog converts cleanly into revenue without major overruns, and the company can raise more capital if needed without crushing the share count further.